428 related articles for article (PubMed ID: 19571295)
1. BRAF mutation in metastatic colorectal cancer.
Tol J; Nagtegaal ID; Punt CJ
N Engl J Med; 2009 Jul; 361(1):98-9. PubMed ID: 19571295
[No Abstract] [Full Text] [Related]
2. Cetuximab for metastatic colorectal cancer.
Roila F; Garassino MC; Ballatori E
N Engl J Med; 2009 Jul; 361(1):95; author reply 96-7. PubMed ID: 19579279
[No Abstract] [Full Text] [Related]
3. Cetuximab for metastatic colorectal cancer.
Bria E; Cuppone F; Di Maio M
N Engl J Med; 2009 Jul; 361(1):95-6; author reply 96-7. PubMed ID: 19579280
[No Abstract] [Full Text] [Related]
4. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
Ince WL; Jubb AM; Holden SN; Holmgren EB; Tobin P; Sridhar M; Hurwitz HI; Kabbinavar F; Novotny WF; Hillan KJ; Koeppen H
J Natl Cancer Inst; 2005 Jul; 97(13):981-9. PubMed ID: 15998951
[TBL] [Abstract][Full Text] [Related]
5. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.
Artale S; Sartore-Bianchi A; Veronese SM; Gambi V; Sarnataro CS; Gambacorta M; Lauricella C; Siena S
J Clin Oncol; 2008 Sep; 26(25):4217-9. PubMed ID: 18757341
[No Abstract] [Full Text] [Related]
6. Beyond KRAS: a new approach in metastatic colorectal cancer.
Winder T; Lenz HJ
Lancet Oncol; 2010 Aug; 11(8):706-7. PubMed ID: 20619738
[No Abstract] [Full Text] [Related]
7. Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point?
Montagnani F; Migali C; Fiorentini G
J Clin Oncol; 2009 Oct; 27(28):e132-3; author reply e134-5. PubMed ID: 19720898
[No Abstract] [Full Text] [Related]
8. How I treat chemorefractory metastatic colorectal cancer.
Chu E
Clin Adv Hematol Oncol; 2018 May; 16(5):340-345. PubMed ID: 29851930
[No Abstract] [Full Text] [Related]
9. Cetuximab for metastatic colorectal cancer.
Garattini S; Torri V; Floriani I
N Engl J Med; 2009 Jul; 361(1):96; author reply 96-7. PubMed ID: 19579281
[No Abstract] [Full Text] [Related]
10. Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer.
Akhoundova D; Pietge H; Hussung S; Kiessling M; Britschgi C; Zoche M; Rechsteiner M; Weber A; Fritsch RM
JCO Precis Oncol; 2021 Nov; 5():1082-1087. PubMed ID: 34994629
[No Abstract] [Full Text] [Related]
11. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression.
Calistri D; Rengucci C; Seymour I; Lattuneddu A; Polifemo AM; Monti F; Saragoni L; Amadori D
J Cell Physiol; 2005 Aug; 204(2):484-8. PubMed ID: 15702478
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab in colorectal cancer.
Sonpavde G
N Engl J Med; 2004 Oct; 351(16):1690-1; author reply 1690-1. PubMed ID: 15483292
[No Abstract] [Full Text] [Related]
13. BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer.
Mao C; Liao RY; Chen Q
J Cancer Res Clin Oncol; 2010 Aug; 136(8):1293-4. PubMed ID: 20514492
[No Abstract] [Full Text] [Related]
14. [RAS testing in metastatic colorectal cancer].
Kirstein MM; Vogel A
Z Gastroenterol; 2014 Sep; 52(9):1095-6. PubMed ID: 25198090
[No Abstract] [Full Text] [Related]
15. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
Dohn LH; Jensen BV; Larsen FO
Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
Hochster HS
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S8-14. PubMed ID: 17145525
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer.
Beatty GL; Giantonio BJ
Expert Rev Anticancer Ther; 2008 May; 8(5):683-8. PubMed ID: 18471041
[TBL] [Abstract][Full Text] [Related]
19. Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.
Abdel-Rahman O
Future Oncol; 2016 Jan; 12(1):25-30. PubMed ID: 26616508
[TBL] [Abstract][Full Text] [Related]
20. RAS mutations in colorectal cancer.
Sunakawa Y; Lenz HJ; Ichikawa W
N Engl J Med; 2013 Nov; 369(22):2159. PubMed ID: 24283233
[No Abstract] [Full Text] [Related]
[Next] [New Search]
